kaiser permanente glp-1 coverage news An employer's guide to GLP-1s for obesity The number of Americans taking

It is backed by ISO 17025-accredited third-party testing and NSF-certified manufacturing

Expert Rev Endocrinol Metab 2025;20:147-52.ArticlePubMed 96

"Weight Management Programs and Services." kp.org

Want to stop your GLP-1

The upfront costs of GLP-1s are an ongoing concern for both public and private payers, and some employers and state Medicaid programs are now restricting coverage, despite recognizing their effectiveness at treating obesity

While they are marketed as a plant-based, prescription-free option, these patches do not contain any actual GLP-1 agonists like semaglutide or tirzepatide, the active ingredients found in FDA-approved medications